Irati
Garmendia Iturbe
Ikertzailea 2019-(e)ra arte
Instituto de Salud Carlos III
Madrid, EspañaInstituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3